Selected Grants
A011-12 SOTERIA (An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH)
Clinical TrialPrincipal Investigator · Awarded by Acceleron Pharma · 2022 - 2027ZENITH A011-14 (A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) WorldHealth Organization (WHO)
Clinical TrialPrincipal Investigator · Awarded by Acceleron Pharma · 2022 - 2026APD-811-303
Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2019 - 2025APD 811-301 - Phase III
Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2019 - 202514th Annual Pulmonary Hypertension Symposium
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Actelion Pharmaceutical US, Inc · 2022 - 2024A011-12 SOTERIA (An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH)
Clinical TrialPrincipal Investigator · Awarded by Acceleron Pharma · 2022 - 2027ZENITH A011-14 (A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) WorldHealth Organization (WHO)
Clinical TrialPrincipal Investigator · Awarded by Acceleron Pharma · 2022 - 2026APD-811-303
Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2019 - 2025APD 811-301 - Phase III
Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2019 - 202514th Annual Pulmonary Hypertension Symposium
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Actelion Pharmaceutical US, Inc · 2022 - 2024Acceleron A011-11 Stellar
Clinical TrialPrincipal Investigator · Awarded by Acceleron Pharma · 2021 - 2024AC-065B302 Select: Radomized double blind placebo controlled parallel group group sequential adaptive Phase 3 study with open label extention period to assess efficacy and safety of Selexipag
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2019 - 2023Phase III of Treprostinil in patients with PH-COPD
Clinical TrialPrincipal Investigator · Awarded by Lung Biotechnology · 2018 - 2023Uptravi® (SelexiPag): tHe usErs dRug rEgistry
ResearchPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2017 - 2023US - Base, observational, drug registry of Opsumit (macitentan) new users in clinical practice (OPUS Registry)
Clinical TrialCo-Principal Investigator · Awarded by Actelion Pharmaceuticals Ltd. · 2015 - 202313th Annual Pulmonary Hypertension Symposium
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Acceleron Pharma · 2021 - 202213th Annual Pulmonary Hypertension Symposium
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Altavant Sciences, Inc. · 2021 - 202112th Annual Pulmonary Hypertension Symposium
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Acceleron Pharma · 2020 - 2021United States Pulmonary Hypertension Scientific Registry
ResearchPrincipal Investigator · Awarded by United States Pulmonary Hypertension Scientific Registry · 2016 - 2021BEAT- An Open label extension of BPS-314d-MR-PAH-303
Clinical TrialPrincipal Investigator · Awarded by Lung Biotechnology · 2018 - 202011th Annual Pulmonary Hypertension Symposium
ConferencePrincipal Investigator · Awarded by Liquidia · 2019 - 2019BPS-314d-MR-PAH-302. BEAT: A Multicenter, Doubled-Blind, Randomized, Placebo-Controlled, Phase 3 Study To Assess The Efficacy And Safety of Oral B.
Clinical TrialPrincipal Investigator · Awarded by Lung Rx, Inc. · 2014 - 2019CardioMEMS
Clinical TrialMentor · Awarded by Pacesetter, Inc. · 2016 - 2018Multicenter, open-label, single-group study to assess the tolerability and the safety of the TRANSITion from inhaled treprostinil to oral selexipag in adult patients with pulmonary arterial hypertension.
Clinical TrialPrincipal Investigator · Awarded by Actelion Pharmaceuticals Ltd. · 2016 - 2018National Biological Sample and Data Repository for PAH
ResearchPrincipal Investigator · Awarded by Cincinnati Children's Hospital Medical Center · 2016 - 2018External Relationships
- Acceleron Pharma ( compound we are using as research is now bought by Merck)
- Actelion Pharmaceuticals Ltd. bought by Janssen (Johnson & Johnson)
- Bayer Healthcare Pharmaceuticals
- Gossamer Bio
- Janssen Research & Development
- Acceleron Pharma ( compound we are using as research is now bought by Merck)
- Actelion Pharmaceuticals Ltd. bought by Janssen (Johnson & Johnson)
- Bayer Healthcare Pharmaceuticals
- Gossamer Bio
- Janssen Research & Development
- Liquidia
- Merck Sharp & Dohme Inc., One Merck Drive, Whitehouse Station, NJ 08889-0100.
- Pulmonary Hypertension Association/US PH registry
- United Therapeutics Corp.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.